Cargando…
Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
PURPOSE: Neuroblastoma is the most common extracranial solid tumour in childhood. It accounts for 15% of all paediatric oncology deaths. In the last few decades, improvement in treatment outcome for high-risk patients has not occurred, with an overall survival rate <30–40%. Many reasons may accou...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112027/ https://www.ncbi.nlm.nih.gov/pubmed/21287160 http://dx.doi.org/10.1007/s00228-010-0966-3 |